Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Lilly/Isis Lung Cancer NDA Possible In 2003; Lymphoma Indication In Phase II

  • News

Executive Summary

An NDA for the Isis drug 3521, licensed to Eli Lilly, could be submitted for non-small cell lung cancer by 2003.

You may also be interested in...



Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study

Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer

Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study

Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer

Lilly Affinitac Launch Supply Will Be Produced By Isis; Deliveries Start In 2003

Isis will begin building launch supply of the non-small cell lung cancer antisense drug Affinitac in early 2003 under a manufacturing agreement with Lilly announced Oct. 1

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS038405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By